Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
G Chir ; 40(6): 587-589, 2019.
Article in English | MEDLINE | ID: mdl-32007124

ABSTRACT

Any inguinal hernia containing the vermiform appendix is called Amyand's hernia. Amyand hernias are very rare and even rarer is the association of Amyand hernia with acute appendicitis. Due to the rarity of this entity, it constitutes a challenging case in terms of diagnosis and treatment. The surgical management is not yet standardized and there are no clear guidelines. There are some controversies regarding whether to perform an appendectomy if appendix appears normal or whether mesh can be used for the hernia repair if appendectomy is performed. We describe a case of Amyand hernia in a 90-year old man with acute appendicitis and we review current literature regarding surgical strategy.


Subject(s)
Appendicitis/complications , Cellulitis/complications , Hernia, Inguinal/complications , Aged, 80 and over , Appendectomy , Appendicitis/diagnostic imaging , Appendicitis/surgery , Cellulitis/diagnostic imaging , Cellulitis/surgery , Hernia, Inguinal/classification , Hernia, Inguinal/diagnostic imaging , Hernia, Inguinal/surgery , Herniorrhaphy/methods , Humans , Incidental Findings , Male , Neoplasms, Germ Cell and Embryonal/complications , Neoplasms, Germ Cell and Embryonal/diagnostic imaging , Neoplasms, Germ Cell and Embryonal/surgery , Orchiectomy , Surgical Mesh , Testicular Neoplasms/complications , Testicular Neoplasms/diagnostic imaging , Testicular Neoplasms/surgery , Tomography, X-Ray Computed , Ultrasonography
2.
Oncogene ; 32(21): 2670-81, 2013 May 23.
Article in English | MEDLINE | ID: mdl-22797070

ABSTRACT

Amplification and rearrangements of the epidermal growth factor receptor (EGFR) gene are frequently found in glioblastoma multiforme (GBM). The most common variant is EGFR variant III (EGFRvIII). Research suggests that EGFRvIII could be a marker for a cancer stem cell or tumor-initiating population. If amplification and rearrangement are early events in tumorigenesis, this implies that they should be preserved throughout the tumor. However, in primary GBM, EGFRvIII expression is focal and sporadic. Unexpectedly, we found EGFR amplification and rearrangement throughout the tumor, including regions with no EGFRvIII expression, suggesting that mechanisms exist to modulate EGFRvIII expression even in the presence of high gene amplification. To study this phenomenon, we characterized three GBM cell lines with endogenous EGFRvIII. EGFRvIII expression was heterogeneous, with both positive and negative populations maintaining the genetic alterations, akin to primary tumors. Furthermore, EGFRvIII defined a hierarchy where EGFRvIII-positive cells gave rise to additional positive and negative cells. Only cells that had recently lost EGFRvIII expression could re-express EGFRvIII, providing an important buffer for maintaining EGFRvIII-positive cell numbers. Epigenetic mechanisms had a role in maintaining heterogeneous EGFRvIII expression. Demethylation induced a 20-60% increase in the percentage of EGFRvIII-positive cells, indicating that some cells could re-express EGFRvIII. Surprisingly, inhibition of histone deacetylation resulted in a 50-80% reduction in EGFRvIII expression. Collectively, this data demonstrates that EGFR amplification and rearrangement are early events in tumorigenesis and EGFRvIII follows a model of hierarchical expression. Furthermore, EGFRvIII expression is restricted by epigenetic mechanisms, suggesting that drugs that modulate the epigenome might be used successfully in glioblastoma tumors.


Subject(s)
Cell Transformation, Neoplastic , Epigenesis, Genetic , ErbB Receptors , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Gene Rearrangement , Glioblastoma , Cell Line, Tumor , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , ErbB Receptors/biosynthesis , ErbB Receptors/genetics , Gene Amplification , Glioblastoma/enzymology , Glioblastoma/genetics , Glioblastoma/pathology , Humans
3.
G Chir ; 33(8-9): 285-96, 2012.
Article in English | MEDLINE | ID: mdl-23017291

ABSTRACT

Early identification of spontaneous pneumomediastinum in an Emergency Department is possible with thoracic ultrasound. We report two cases of spontaneous pneumomediastinum, diagnosed in a 26-year old man with chronic asthma and a 19-year old athlete, and discuss the role of thoracic US alongside conventional X-ray and thoracic CT in emergency medicine. The patients were transferred to an Emergency Department, where conservative treatment produced a good outcome. The greater sensitivity and specificity of thoracic US over conventional supine X-ray in the detection of occult pneumothorax is ever more appreciated. However, training in the diagnosis of pneumomediastinum is required.


Subject(s)
Emergency Treatment , Mediastinal Emphysema/diagnostic imaging , Mediastinal Emphysema/surgery , Adult , Humans , Male , Ultrasonography , Young Adult
4.
Br J Cancer ; 106(5): 883-8, 2012 Feb 28.
Article in English | MEDLINE | ID: mdl-22315050

ABSTRACT

BACKGROUND: The human epidermal growth factor receptor (EGFR) is an important therapeutic target in oncology, and three different types of EGFR inhibitors have been approved for the treatment of cancer patients. However, there has been no clear association between the expression levels of EGFR protein in the tumours determined by the FDA-approved EGFR PharmDx kit (Dako) or other standard anti-EGFR antibodies and the response to the EGFR inhibitors. METHOD: In this study, we investigated the potential of our anti-EGFR monoclonal antibodies (mAbs; ICR9, ICR10, ICR16) for immunohistochemical diagnosis of wild-type EGFR and/or the type-III deletion mutant form of EGFR (EGFRvIII) in formalin-fixed, paraffin-embedded human tumour specimens. RESULTS: We found that the anti-EGFR mAb in the EGFR PharmDx kit stained both wild-type and EGFRvIII-expressing cells in formalin-fixed, paraffin-embedded sections. This pattern of EGFR immunostaining was also found with our anti-EGFR mAb ICR16. In contrast, mAbs ICR10 and ICR9 were specific for the wild-type EGFR. CONCLUSION: We conclude that mAbs ICR9 and ICR10 are ideal tools for investigating the expression patterns of wild-type EGFR protein in tumour specimens using immunohistochemistry, and to determine their prognostic significance, as well as predictive value for response to therapy with EGFR antibodies.


Subject(s)
Antibodies, Monoclonal/immunology , ErbB Receptors/analysis , Neoplasms/diagnosis , Cell Line, Tumor , ErbB Receptors/genetics , ErbB Receptors/immunology , Humans , Immunohistochemistry , Mutant Proteins/analysis , Mutant Proteins/immunology , Neoplasms/chemistry , Paraffin Embedding , Predictive Value of Tests
5.
Oncogene ; 30(2): 234-44, 2011 Jan 13.
Article in English | MEDLINE | ID: mdl-20871632

ABSTRACT

The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family and have been implicated in tumorigenesis. One isoform in particular, JNK2α, has been shown to be frequently activated in primary brain tumors, to enhance several tumorigenic phenotypes and to increase tumor formation in mice. As JNK is frequently activated in non-small cell lung carcinoma (NSCLC), we investigated the role of the JNK2α isoform in NSCLC formation by examining its expression in primary tumors and by modulating its expression in cultured cell lines. We discovered that 60% of the tested primary NSCLC tumors had three-fold higher JNK2 protein and two- to three-fold higher JNK2α mRNA expression than normal lung control tissue. To determine the importance of JNK2α in NSCLC progression, we reduced JNK2α expression in multiple NSCLC cell lines using short hairpin RNA. Cell lines deficient in JNK2α had decreased cellular growth and anchorage-independent growth, and the tumors were four-fold smaller in mass. To elucidate the mechanism by which JNK2α induces NSCLC growth, we analyzed the JNK substrate, signal transducer and activator of transcription 3 (STAT3). Our data demonstrates for the first time that JNK2α can regulate the transcriptional activity of STAT3 by phosphorylating the Ser727 residue, thereby regulating the expression of oncogenic genes, such as c-Myc. Furthermore, reintroduction of JNK2α2 or STAT3 restored the tumorigenicity of the NSCLC cells, demonstrating that JNK2α is important for NSCLC progression. Our studies reveal a novel mechanism in which phosphorylation of STAT3 is mediated by a constitutively active JNK2 isoform, JNK2α.


Subject(s)
Adenocarcinoma, Bronchiolo-Alveolar/enzymology , Carcinoma, Non-Small-Cell Lung/enzymology , Carcinoma, Squamous Cell/enzymology , Cell Transformation, Neoplastic/metabolism , Lung Neoplasms/enzymology , Mitogen-Activated Protein Kinase 9/metabolism , Aged , Aged, 80 and over , Animals , Cell Line, Tumor , Female , Humans , Isoenzymes/metabolism , Lung/enzymology , Male , Mice , Mice, SCID , Middle Aged , Mitogen-Activated Protein Kinase 9/analysis , RNA, Small Interfering/pharmacology , STAT3 Transcription Factor/metabolism
6.
Gene Ther ; 16(2): 279-90, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19037240

ABSTRACT

Recombinant Semliki Forest virus (SFV) is an attractive viral vector system owing to its ability to allow high efficiency of viral protein expression. To produce recombinant pseudotyped human immunodeficiency virus type 1 (HIV-1) virions, we designed a chimeric SFV/HIV vector system that contains both the HIV-1 cis- and trans-acting elements under the transcriptional control of the SFV replicase and investigated the ability of the hybrid SFV/HIV system to produce lentiviral particles capable of transducing target cells. Co-transfection of target cells with the two helper SFV packaging system RNAs along with each SFV/Gag-Pol, SFV/VSV(G) as well as SFV/HIV-1 vector unit replicon led to the generation of efficient transducing competent recombinant SFV/HIV particles. In contrast, co-transduction of target cells with the SFV/HIV chimeric virions produced recombinant particles with low transducing ability. Our data suggest that both the genomic and the subgenomic RNAs containing the HIV-1 vector unit were negatively selected for incorporation into recombinant particles, despite the fact that the SFV-driven HIV-1 vector replicon was the only one containing a lentiviral packaging sequence. The results of this study provide insights relevant to the design of chimeric lentiviral vectors.


Subject(s)
HIV-1/genetics , Semliki forest virus/genetics , Trans-Activators/biosynthesis , Cell Line , Genetic Vectors/genetics , Humans , Recombination, Genetic , Replicon/genetics , Trans-Activators/genetics , Transduction, Genetic , Virion/genetics
7.
Gene Ther ; 12(4): 299-310, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15496956

ABSTRACT

Immune-based approaches of cell therapy against viral pathogens such as the human immunodeficiency virus type 1 (HIV-1) could be of primary importance for the control of this viral infection. Here, we designed a chimeric cell surface receptor (105TCR) to provide primary human T-lymphocytes with antibody-type specificity for the HIV-1 envelope glycoprotein. This receptor includes the single chain Fv domain of the neutralizing anti-gp120 human monoclonal antibody F105, CD8alpha hinge and the transmembrane and the cytoplasmic domains of TCRzeta. Our results show that 105TCR is expressed at the cellular surface and is capable of recognizing the HIV-1 envelope glycoprotein inducing highly efficient effector T-cell responses, including extracellular signal-regulated kinase phosphorylation and cytokine secretion. Moreover, human primary CD8+ T-lymphocytes transduced by oncoretroviral and lentiviral vectors containing the 105TCR gene are able to mediate in vitro-specific cytolysis of envelope-expressing cells and HIV-1-infected CD4+ T-lymphocytes. These findings suggest that 105TCR is particularly suited for in vivo efficacy studies.


Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Genetic Therapy/methods , HIV Envelope Protein gp120/immunology , HIV Infections/therapy , Immunotherapy, Adoptive/methods , Receptors, Antigen, T-Cell/genetics , Animals , Antibody Specificity , COS Cells , Cell Line , Chimera , Chlorocebus aethiops , Flow Cytometry , Gene Expression , HIV Infections/immunology , HIV-1 , Humans , Jurkat Cells , Receptors, Antigen, T-Cell/immunology , Reverse Transcriptase Polymerase Chain Reaction
8.
J Hypertens ; 19(8): 1489-96, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11518858

ABSTRACT

BACKGROUND: Distal echo-Doppler velocimetric indices are widely used for revealing the presence of a renal artery stenosis but there is scarce information as to whether they reflect the renal hemodynamics in stenotic and nonstenotic kidneys. OBJECTIVES AND METHODS: We evaluated the pulsatility and resistive indices (PI and RI), acceleration (A) and acceleration time (At) and correlated their values with those of effective renal plasma flow (ERPF), glomerular filtration rate (GFR), renal vascular resistance (RVR) and filtration fraction (FF) estimated by single kidney scintigraphy in 24 kidneys with 70-95% renal artery stenosis (atherosclerotic n = 17, fibromuscular n = 7) and in 27 non-stenotic kidneys (11 contralateral to renal artery stenosis and 16 of patients with essential hypertension). In patients with stenotic kidneys, these measurements were repeated within 7 days after a successful percutaneous transluminal renal angioplasty (PTRA) (in 11 arteries performed in combination with stent implantation). RESULTS: Prior to dilation we found that the stenotic kidneys had significantly lower values of ERPF, GFR and higher RVR than the non-stenotic kidneys and that these hemodynamic alterations were associated with those, also statistically significant, of the four velocimetric indices. In non-stenotic kidneys, there were highly significant relationships between PI and ERPF, and RVR (r = -0.68 and 0.81 respectively P < 0.01); similar relationships were found for RI (r = -0.67 and 0.78 P < 0.01) whereas no such correlations were found between these two velocimetric indices and GFR and FF; also no correlations were found between A and Atand ERPF, GFR, RVR and FF. In stenotic kidneys no significant correlations were found between any of the velocimetric and the hemodynamic indices. Renal artery dilation induced clear cut increments in ERPF, GFR and reduction in RVR in post-stenotic kidneys, which were associated with normalization of all four velocimetric indices. No relationships were observed between the renal hemodynamic and the velocimetric changes induced by dilation; however in post-stenotic kidneys the relationships between PI and RI, ERPF and RVR were restored as in nonstenotic kidneys. CONCLUSIONS: These data indicate that PI and RI can be used to assess ERPF and RVR both in non-stenotic and post-stenotic kidneys; however, none of the velocimetric indices examined in this study can provide valid informations on the renal hemodynamics of stenotic kidneys and on their changes induced by PTRA.


Subject(s)
Blood Flow Velocity , Renal Artery Obstruction/diagnostic imaging , Renal Artery Obstruction/physiopathology , Renal Circulation , Ultrasonography, Doppler , Adolescent , Adult , Aged , Angioplasty , Female , Hemodynamics , Humans , Male , Middle Aged , Postoperative Period , Pulse , Reference Values , Renal Artery Obstruction/surgery , Vascular Resistance
9.
J Am Assoc Gynecol Laparosc ; 7(1): 71-5, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10648742

ABSTRACT

STUDY OBJECTIVE: To investigate the pain and acceptability of diagnostic hysteroscopy performed without local anesthesia. DESIGN: Prospective, observational study (Canadian Task Force classification II-2). SETTING: University-associated department of obstetrics and gynecology. PATIENTS: The 1144 consecutive women who underwent diagnostic hysteroscopy. INTERVENTIONS: Diagnostic hysteroscopy and endometrial biopsy as indicated. MEASUREMENTS AND MAIN RESULTS: Patients were asked to rate the pain experienced on a 10-cm visual analog scale and to state if they were willing to repeat the procedure. The mean pain score was 4.7 +/- 2.5; 398 patients (34.8%) experienced severe pain. No risk factors for painful hysteroscopy were found, although abnormality of the cervical canal was associated with high pain scores. Acceptance of the procedure was high, 83.0% (950 women). CONCLUSION: Diagnostic hysteroscopy is a painful procedure even when performed with atraumatic technique by experienced surgeons. Most women, however, stated they were willing to have a second procedure under the same conditions.


Subject(s)
Ambulatory Care , Hysteroscopy , Pain , Patient Acceptance of Health Care , Anesthesia, Local , Female , Humans , Hysteroscopy/adverse effects , Middle Aged , Pain/etiology , Pain Measurement , Prospective Studies , Uterine Diseases/diagnosis
10.
Mol Biochem Parasitol ; 99(2): 167-81, 1999 Apr 30.
Article in English | MEDLINE | ID: mdl-10340482

ABSTRACT

Two major protein phosphatase (PP) activities were purified from cytosolic extracts of the erythrocytic stage of the malaria parasite, Plasmodium falciparum. Both enzymes were specific for phosphoserine and phosphothreonine residues with very little activity against phosphotyrosine residues. The biochemical properties of the enzymes suggested their strong similarity with eukaryotic PP2A and PP2B protein phosphatases. Both enzymes preferentially dephosphorylated the alpha subunit of phosphorylase kinase, and were resistant to inhibitor-1. The PP2A-like enzyme required Mn2+ for activity and was inhibited by nanomolar concentrations of okadaic acid (OA). The cDNA sequence of the PP2A-like enzyme was identified through a match of its predicted amino acid sequence with the N-terminal sequence of the catalytic subunit. The PP2B-like (calcineurin) enzyme was stimulated by calmodulin and Ca2+ or Ni2+, but was resistant to OA. Malarial calcineurin was strongly and specifically inhibited by cyclosporin A (CsA) only in the presence of wild type P. falciparum cyclophilin but not a mutant cyclophilin. The inhibition was noncompetitive, and provides a potential explanation for the cyclosporin-sensitivity of the parasite. There was no significant quantitative difference in the total protein Ser/Thr phosphatase activity among the ring, trophozoite, and schizont stages.


Subject(s)
Calcineurin Inhibitors , Cyclosporine/pharmacology , Peptidylprolyl Isomerase/pharmacology , Phosphoric Monoester Hydrolases/metabolism , Plasmodium falciparum/enzymology , Protozoan Proteins/metabolism , Amino Acid Sequence , Animals , DNA, Complementary/analysis , Humans , Molecular Sequence Data , Mutation , Okadaic Acid/pharmacology , Peptidylprolyl Isomerase/genetics , Phosphoric Monoester Hydrolases/isolation & purification , Phosphoserine/metabolism , Phosphothreonine/metabolism , Protozoan Proteins/isolation & purification , Sequence Homology, Amino Acid
11.
Appl Opt ; 38(10): 2018-27, 1999 Apr 01.
Article in English | MEDLINE | ID: mdl-18319759

ABSTRACT

Fritz's method [Opt. Eng. 23, 379 (1984)] of using Zernike polynomials to assess the absolute planarity of test plates is revisited. A refinement is described that takes into account the data decorrelation that appears in experiments. An uncertainty balance is defined by propagation of error contributions through the steps of the method. The resultant measuring procedure is demonstrated on a data set from experiments, and a nanometer level of uncertainty is achieved.

12.
Appl Opt ; 37(21): 4656-62, 1998 Jul 20.
Article in English | MEDLINE | ID: mdl-18285922

ABSTRACT

We present the mechanical and actuator design of an adaptive secondary mirror that matches the optical requirements of the active and adaptive corrections. Conceived for the particular implementation for the 6.5-m conversion of the multiple-mirror telescope, with small variations of the input parameters this study is suitable for applications for telescopes of the same class. We found that a three-layer structure, i.e., a thin deformable shell, a thick reference plate, and a third plate that acts as actuator support and heat sink, is able to provide the required mechanical stability and actuator density. We also found that a simple electromagnetic actuator can be used. This actuator, when optimized, will dissipate a typical power of a few tenths of watts.

13.
Am J Gastroenterol ; 91(3): 559-64, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8633509

ABSTRACT

OBJECTIVES: The i.v. load of fructose causes a significantly higher adenosine triphosphate (ATP) degradation and uric acid production in cirrhotic patients than in healthy controls. Resynthesis of ATP from adenosine diphosphate (ADP) may be facilitated by the phosphorylated compound fructose 1,6-diphosphate, which is used as energy support in parenteral nutrition. The aim of our research was to evaluate: 1) The 1-h uricemic effect of i.v. fructose (0.5 g/kg body weight) in 10 healthy controls and in 78 patients with differenct stages of non-alcoholic chronic liver damage associated or not with malnutrition or hepatocellular carcinoma; and 2) the effect of fructose 1,6-diphosphate (5 g/50 ml) administered i.v. after fructose infusion on the induced uricemia in a subgroup of 13 patients with well compensated cirrhosis. RESULTS AND CONCLUSIONS: The increase of uricemia above the basal level after fructose infusion was significantly higher (p < 0.01) in cirrhotics (3 mg/dl) than in controls (1.2 mg/dl) and in patients with chronic hepatitis (1.9 mg/dl) and was completely reversed by fructose 1,6-diphosphate in the patients tested. Neither Child-Pugh classes of cirrhosis nor malnutrition (present in about 50% of the patients) or hepatocarcinoma significantly affected the fructose-induced uricemia. Therefore, the fructose test efficiently differentiates cirrhotics from chronic hepatitis patients and healthy subjects, but it does not distinguish the various stages of the progression of cirrhosis or its complications.


Subject(s)
Fructose-Bisphosphatase , Fructose , Liver Cirrhosis/blood , Uric Acid/blood , Adult , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/diagnosis , Diagnosis, Differential , Female , Fructose/administration & dosage , Fructose-Bisphosphatase/administration & dosage , Humans , Infusions, Intravenous , Liver Cirrhosis/diagnosis , Liver Neoplasms/blood , Liver Neoplasms/diagnosis , Male , Middle Aged , Nutrition Disorders/blood , Nutrition Disorders/diagnosis , Nutritional Status
14.
Ital J Gastroenterol ; 27(6): 335-9, 1995.
Article in English | MEDLINE | ID: mdl-8563001

ABSTRACT

The influence of the hydrophobic-hydrophilic properties of bile salts (BS) on acute ethanol hepatotoxicity was investigated. Bile flow, biliary BS secretion and enzyme (LDH,AST) release in the perfusate were measured before and after exposure to low (0.1%) or high (1%) doses of ethanol in in vitro isolated livers perfused with 1 microM/min taurocholate (TCA), tauroursodeoxycholate (TUDCA) or taurodeoxycholate (TDCA). Ethanol promotes a rapid decrease of basal bile flow and BS secretion in TCA-perfused livers [-28% of basal values with 0.1% (N = 6), and -35% with 1% ethanol (N = 6)]. Bile flow and BS secretion were minimally decreased by ethanol in livers perfused with a hydrophilic BS (TUDCA) [-8% decrease of basal values with 0.1% ethanol (N = 6), and -10% with 1% ethanol (N = 9); p < 0.02 vs TCA-perfused livers]. In contrast, when livers were perfused with a hydrophobic BS (TDCA), ethanol showed a higher cholestatic effect than either TCA- or TUDCA-perfused livers. Enzyme release in the perfusate was not modified by 0.1% ethanol, while 1% ethanol promoted a 4-5 fold increase in LDH and AST release in the perfusate of TCA-perfused livers with respect to a mere 2-fold increase in TUDCA-perfused livers and a 6-7 fold increase in TDCA perfused livers (p < 0.03). In conclusion, we showed that TUDCA almost completely counteracts the cholestatic and cytolitic effects promoted by ethanol in the isolated perfused rat liver.


Subject(s)
Bile/physiology , Ethanol/toxicity , Liver/drug effects , Taurochenodeoxycholic Acid/physiology , Taurocholic Acid/physiology , Taurodeoxycholic Acid/physiology , Animals , Liver/physiology , Male , Perfusion , Rats , Rats, Wistar
15.
Haematologica ; 80(3): 241-3, 1995.
Article in English | MEDLINE | ID: mdl-7672717

ABSTRACT

Primary splenic lymphoma is a relatively infrequent disease; the diagnosis of this entity is currently made with splenectomy. In a 52-year-old female with left upper quadrant abdominal pain, ultrasound showed a normal-sized spleen with an internal hypoechoic focal lesion. Ultrasonically-guided fine-needle aspiration and tissue core biopsy of the splenic lesion showed non-Hodgkin's lymphoma (NHL). At the time of presentation there was no evidence of involvement of lymph nodes, bone marrow or any other organ. A diagnosis of primary splenic non-Hodgkin's lymphoma was made and the patient underwent laparotomy with splenectomy. Histologic examination of the spleen confirmed the diagnosis: low-grade NHL confined to the spleen. The patient is well and in complete remission seven months after diagnosis. The purpose of this paper is to report a rare occurrence of primary splenic lymphoma and to demonstrate the possibility of making this diagnosis by percutaneous guided biopsy.


Subject(s)
Lymphoma/pathology , Splenic Neoplasms/pathology , Biopsy, Needle , Female , Humans , Middle Aged , Ultrasonics
16.
Am J Gastroenterol ; 90(2): 263-9, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7847298

ABSTRACT

OBJECTIVES: The purpose of this study was to compare, within a randomized controlled trial, the efficacy of recombinant interferon-alpha in combination with ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic HCV hepatitis. METHODS: Forty anti-HCV positive chronic hepatitis patients with ALT levels persistently greater than 3 times the upper normal level were randomized to receive either interferon-alpha (6 million units three times/wk for 6 months) plus ursodeoxycholic acid (10 mg/kg/day for 9 months) (n = 20) or interferon-alpha (6 million units three times/wk for 6 months) alone (n = 20). Disease activity was monitored monthly by ALT measurement until 18 months after interferon-alpha cessation. Serum HCV-RNA was measured at baseline and after 6, 9, and 24 months. Liver biopsies (basal and at the 9th month) were evaluated blindly and scored by Knodell's criteria. RESULTS: The probability of full or partial response during interferon-alpha treatment was similar in the two groups. The probability of biochemical relapse (i.e, any persistent return of ALT above normal) after 18-month of posttreatment follow-up was 75% in both the combination and the monotherapy group. Relapse, however, occurred significantly later in the combination than in the monotherapy group (6.6 +/- 5.4 [SD] months and 1.8 +/- 1.6 months after IFN-alpha cessation, respectively, p < 0.02). Severe biochemical relapse (i.e., a persistent ALT elevation greater than 3 times normal) occurred more frequently and earlier (p = 0.05) in patients treated with interferon-alpha (58.3%) than in those receiving the combination therapy (27.3%). The cumulative duration of normalized ALT periods during and after treatment was significantly greater (p = 0.005, chi 2) in patients treated with IFN-alpha + UDCA than with monotherapy (189/354 months vs 136/323 months. Lobular necrosis improved in both groups (p = 0.056 and p = 0.001, respectively), whereas portal inflammation improved (p = 0.009) only in the combination therapy group. Among the 30 patients who were viremic at entry, plasma HCV-RNA was no longer detectable after 6 months in four from the combination group and in five from the monotherapy group, yet all patients but one returned HCV-RNA positive 3 months after interferon-alpha cessation and were still viremic after 18 months. Cox's multiple regression identified the histological degree of posttreatment portal inflammation as the sole positive indicator of relapse. CONCLUSIONS: The combination of interferon-alpha and ursodeoxycholic acid prolongs the efficacy of interferon-alpha alone in chronic hepatitic C by delaying the probability of biochemical relapse and/or by reducing its severity, without affecting HCV viremia.


Subject(s)
Hepatitis C/drug therapy , Interferon-alpha/therapeutic use , Ursodeoxycholic Acid/therapeutic use , Adult , Chronic Disease , Drug Therapy, Combination , Female , Follow-Up Studies , Hepatitis C/blood , Humans , Male , Middle Aged , Probability , Recombinant Proteins/therapeutic use , Recurrence , Regression Analysis , Treatment Outcome
17.
Clin Nephrol ; 23(2): 68-73, 1985 Feb.
Article in English | MEDLINE | ID: mdl-3987101

ABSTRACT

The possible relationship between erythrocyte (RBC) function and secondary hyperparathyroidism (HPT) was examined in 35 uremic patients on maintenance hemodialysis. Mechanical tests (i.e., osmotic fragility and deformability) were used to assess RBC function. Secondary HPT was evaluated by means of serum biochemistry (parathyroid hormone, calcium, phosphorus, and alkaline phosphatase) and radiographic examinations (X-ray films of the hand skeleton). Sixteen sex and age-matched normal volunteers acted as controls. This study shows that the mechanical properties of RBC were indeed markedly altered in hemodialysis patients when compared with controls. No significant correlations between either the osmotic fragility or the deformability of RBC and the hematochemical changes associated with secondary HPT were found. No differences in RBC function tests were found as far as the activity (alkaline phosphatase) or the severity (X-ray findings) of secondary HPT are concerned. Effective treatment of secondary HPT by either pharmacological means (1,25-dihydroxycholecalciferol) or surgical removal was not associated with consequent improvement in RBC function. These findings clearly speak against secondary HPT as a major cause of RBC dysfunction in uremic patients on maintenance hemodialysis.


Subject(s)
Erythrocyte Deformability , Erythrocytes/physiology , Hyperparathyroidism, Secondary/blood , Renal Dialysis , Uremia/blood , Adolescent , Adult , Aged , Alkaline Phosphatase/blood , Calcium/blood , Female , Humans , Hyperparathyroidism, Secondary/etiology , Male , Middle Aged , Osmotic Fragility , Parathyroid Hormone/blood , Parathyroid Hormone/metabolism , Phosphorus/blood , Uremia/physiopathology , Uremia/therapy
18.
Int J Artif Organs ; 7(6): 337-40, 1984 Nov.
Article in English | MEDLINE | ID: mdl-6526528

ABSTRACT

To evaluate the relative contribution that dialyzer membrane composition and geometry make to hemodialysis-associated platelet loss, the effect of a single dialysis with three different types of dialyzers on platelet count was examined on a cross-over basis in 19 uremic patients on maintenance hemodialysis. Also, the plasma levels of antithrombin-iii before and after dialysis were measured, but no significant variations were found regardless of which dialyzer was in use. Our patients suffered significant platelet loss during cuprophan dialysis, but not polyacrylonitrile dialysis. More than 99% of initial circulating platelets were recovered at the end of polyacrylonitrile dialysis, whereas cuprophan dialysis did leave a significantly lower percentage of circulating platelets (p less than 0.05). The internal comparison of results obtained with the two cuprophan dialyzers used shows no difference as to the dialyzer geometry (flat plate or hollow fiber). This indicates that the membrane composition is the major factor influencing hemodialysis-associated platelet loss. We suggest that patients with low platelet count and/or with risk of bleeding may benefit from polyacrylonitrile dialysis.


Subject(s)
Membranes, Artificial , Renal Dialysis/adverse effects , Thrombocytopenia/etiology , Uremia/blood , Acrylic Resins , Adult , Aged , Antithrombin III/analysis , Cellulose/analogs & derivatives , Female , Humans , Male , Middle Aged , Platelet Count , Uremia/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...